Merck & Co to launch production of four drugs in Russia

20 June 2016
merck-big

The USA’s Merck & Co (NYSE: MRK) has signed an agreement with Akrikhin, one of Russia’s largest drugmakers, on the establishment of production of its drugs at Akrikhin’s facilities in the Moscow region.

Under the terms of the agreement, the partners will launch the production of four drugs for the treatment of cardiovascular diseases and type 2 diabetes mellitus from Merck Sharp & Dohme (MSD), as the company is known outside of North America.

The production of the first drug (with the active ingredient simvastatin, Merck’s now off-patent cholesterol drug Zocor), which is used for secondary prevention of cardiovascular events, will commence next month, while the production of three other drugs, including the anti-diabetic Januvia (sitagliptin), is expected to be launched next year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical